Transfection Technologies Market by Product (Kits, Equipment), Method (Physical (Electroporation, Microinjection), Biochemical (Lipofection, Calcium Phosphate), Viral), Application (Biomedical Research, Therapeutic Delivery) - Global Forecast to 2028

Transfection Technologies Market by Product (Kits, Equipment), Method (Physical (Electroporation, Microinjection), Biochemical (Lipofection, Calcium Phosphate), Viral), Application (Biomedical Research, Therapeutic Delivery) - Global Forecast to 2028

The transfection technologies market is projected to reach USD 1.8 billion by 2028 from an estimated USD 1.2 billion in 2023, at a CAGR of 9.4% during the forecast period. The growth of this market can be attributed to the technological advancements in physical transfection methods, increasing research and development efforts in cell biology, growing focus on personalized medicines, and rising demand for advanced therapeutic products.

“The kits & reagents segment accounted for the largest share by product type in 2022.”

In 2022, the kits & reagents segment accounted for the largest share of product type in the global transfection technologies market. The factors like growing demand for high quality reagents to transfect nucleic acids into cells. The increasing focus on development of personalized medicines is also driving the growth of this market. Furthermore, the market share of the kits & reagents market is expected to grow simultaneously with the increasing need for advanced therapies.

“The North America dominated the transfection technologies market during the forecast period of 2023-2028.”

North America dominated the global transfection technologies market in 2022. This dominance is attributed to the presence of academic and research centers, often associated with drug discovery and development. Additionally, the region is experiencing increased investments in biologics and advanced dosage forms. The growing need to expedite the drug development process, which typically spans 10 to 12 years, has further fueled the demand for transfection technologies. Consequently, the North America market is witnessing growth due to the development of novel drug products and the growing research and development in cell biology efforts in the region.

The primary interviews conducted for this report can be categorized as follows:

By Respondent: Supply Side- 70% and Demand Side 30%

By Designation: Managers - 45%, CXO & Directors - 30%, and Executives - 25%

By Region: North America -35%, Europe -20%, Asia-Pacific -25%, Latin America -15% and Middle East & Africa- 5%

List of Companies Profiled in the Report:

Thermo Fisher Scientific Inc. (US)

Bio-Rad Laboratories, Inc. (US)

QIAGEN (Netherlands)

Merck KGaA (Germany)

Sartorius AG (Polyplus) (Germany)

Lonza (Switzerland)

F. Hoffmann-La Roche Ltd (Switzerland)

Agilent Technologies, Inc. (US)

MaxCyte (US)

Revvity (US)

Takara Bio Inc. (Japan)

Promega Corporation (US)

Danaher Corporation (US)

BOC Sciences (US)

RJH BIOSCIENCES (Canada)

Synvolux (Netherlands)

Altogen Biosciences (US)

BioIVT (US)

Incella GmbH (Germany)

InvivoGen (France)

Phoreus Biotech (US)

STEMCELL Technologies (Canada)

EZ Biosystems (US)

OZ Biosciences(France)

chemicell GmbH (Germany)

Research Coverage:

This research report categorizes the transfection technologies market by product type (kits & reagents and equipment), method (physical transfection (electroporation, bistolic technology, microinjection, and other physical transfection methods), biochemical transfection (lipofection, calcium phosphate, cationic polymer, dendrimer mediated transfection, and DEAE dextran), viral vector transfection), application (biomedical research, therapeutic delivery, protein production, and cell based microarray), end user (pharmaceutical and biotechnology companies, Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO), academic and research institutes, and other end users)

The report's scope encompasses detailed information regarding major influencing factors such as drivers, trends, challenges, and opportunities shaping the growth of the transfection technologies market. A comprehensive analysis of key industry players has been conducted to offer insights into their business overview, products, key strategies, collaborations, partnerships, and agreements. The report also covers recent developments, including new product launches, mergers, and acquisitions, in the transfection technologies market.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall transfection technologies market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

Analysis of key drivers (Increasing demand for cell and gene therapy, rising research activities and R&D funding, technological advancements), restraints (limited efficiency of transfection methods, adoption of alternative methods), opportunities (rising focus on personalized medicine, growth opportunities in emerging economies), and challenges (concerns related to cytotoxicity and transfection in hard-to-transfect cells, challenges associated with large scale transfection processes) influencing the growth of the market.

Product Development/Innovation: Detailed insights on newly launched products of the transfection technologies market

Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.

Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the transfection technologies market

Competitive Assessment: Thermo Fisher Scientific Inc. (US), Bio-Rad Laboratories, Inc. (US), QIAGEN (Netherlands),Merck KGaA (Germany), Sartorius AG (Polyplus) (Germany), Lonza (Switzerland), F. Hoffmann-La Roche Ltd (Switzerland), Agilent Technologies, Inc. (US), MaxCyte (US), Revvity (US), Takara Bio Inc. (Japan), Promega Corporation (US), Danaher Corporation (US), BOC Sciences (US), RJH BIOSCIENCES (Canada), Synvolux (Netherlands), Altogen Biosciences (US), BioIVT (US), Incella GmbH (Germany), InvivoGen (France), Phoreus Biotech (US), STEMCELL Technologies (Canada), EZ Biosystems (US), OZ Biosciences(France), chemicell GmbH (Germany), and among others in the market.